Related Experiment Videos
Vulvovaginal pyoderma gangrenosum secondary to rituximab therapy
Shreya Dixit1, Priya Selva-Nayagam, Ian Hamann
11Northern Clinical School, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales; 2Royal Adelaide Hospital, Adelaide, South Australia; and 3Mid North Coast Dermatology, Port Macquarie, New South Wales, Australia.
Abstract:
Rituximab is being used increasingly for the treatment of B-cell malignancies and nonmalignant conditions. Pyoderma gangrenosum is a rare neutrophilic dermatosis, which can be either idiopathic or associated with underlying systemic inflammatory conditions. We present a series of 4 patients who presented with ulcerative pyoderma gangrenosum in the vulvovaginal area after treatment with rituximab.
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Acute Pyelonephritis II: Diagnostic Studies and Management
Staphylococcal Skin Infections
Acute Pyelonephritis I: Introduction
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...